NIJMEGEN, The Netherlands--(BUSINESS WIRE)-- Staten Biotechnology B.V. announced today the initiation of dosing of the Company’s lead asset, STT-5058, in a First-in-Human clinical study.
NIJMEGEN, The Netherlands--(BUSINESS WIRE)--Staten Biotechnology B.V. announced today the initiation of dosing of the Company’s lead asset, STT-5058, in a First-in-Human clinical study.